irs program accomplishments · form 990 part iii · fy2022
What they reported doing
- #1 primary $2.67MVACCINE ADVOCACY, PUBLIC AFFAIRS, AND POLICY: IAVI WORKS WITH POLICY MAKERS, ADVOCATES, AND REPRESENTATIVES OF THE COMMUNITIES WHERE DISEASE BURDEN IS GREATEST TO SUPPORT SCIENTIFIC RESEARCH AND DEVELOPMENT FOR ACCESSIBLE BIOMEDICAL PREVENTIVES AND TREATMENTS.
named programs · 5 · from sources
What they call their work
Advocacy and Community Engagement
Works with policymakers, advocates, and communities to support equitable access to vaccines and inclusive research practices
Emerging Infectious Diseases Vaccine Program
Develops rVSV-based vaccine candidates for Marburg, Sudan, and Bundibugyo viruses, with rapid response deployment during outbreaks
HIV Vaccine Development
Advances next-generation HIV vaccines using sequential immunization strategies and broadly neutralizing antibodies (bnAbs), including mRNA-based candidates in clinical trials
Lassa Vaccine Clinical Trials
Conducts Phase 2 trials of a single-dose rVSV-based Lassa vaccine in West Africa, supported by epidemiological and community engagement work
TB Vaccine Development
Advances MTBVAC and other TB vaccine candidates through clinical trials and policy advocacy, with focus on high-burden countries
activities · 3 groups
What they do
-
Global Tuberculosis Drug Development and Access 2 activities
- Global capacity building and scientific trainingStrengthens local research capacity in Africa and India by training scientists, conducting clinical trials, and supporting equitable partnerships. Operates the Leadership Development Program for HIV vaccine research leaders and builds regional expertise through initiatives like the IAVI G003 study.
- Vaccine advocacy and public policy engagementAdvances biomedical prevention research through advocacy, public affairs, and policy work with policymakers, advocates, and communities in high-disease-burden regions. Participates in major scientific conferences and promotes equitable access to vaccines.
-
-
Biomedical Research and Innovation 1 activity
- Vaccine and antibody research and developmentConducts end-to-end research and development of vaccines and broadly neutralizing antibodies (bnAbs) for HIV, tuberculosis, Lassa fever, Sudan virus, Marburg virus, Bundibugyo ebolavirus, and other emerging infectious diseases, using platforms such as mRNA and recombinant vesicular stomatitis virus (rVSV). Advances candidates from concept to clinical testing through internal research and global partnerships.
-
-
Uncategorized 1 activity
- Clinical and community-based implementation of vaccine trialsConducts direct-service activities including ring vaccination trials for Sudan virus disease in Uganda and community engagement efforts in South Africa, Kenya, and other locations as part of vaccine development programs. Delivered first vaccinations within four days of an outbreak declaration in 2025.
-
financials · form 990 · fy2024
revenue
Total revenue$131.18M
Contributions & grants$126.01M96%
Program service revenue$2.51M2%
Investment income$2.30M2%
Other revenue$365K
expenses
Total expenses$143.04M
Program expenses89%
Admin / overhead11%
Fundraising0%
Salaries & benefits$50.84M
Grants paid out$33.69M
Largest expense lineCompensation
balance sheet
Total assets$129.85M
Cash$18.63M
Investments$36.53M
Liabilities$78.46M
Net assets$51.39M
Liquid reserves4.6 mo
5 years on record · 2020–2024 · YoY revenue +1.2%
leadership · form 990 part vii · fy2024
Who runs it
paid leadership · 11
| Name | Title | Hours/wk | Compensation |
|---|---|---|---|
| MARK B FEINBERG | PRESIDENT/CEO | 35 | $784K |
| ANA CESPEDES MONTOYA | CHIEF OPERATING OFFICER | 35 | $614K |
| SWATI GUPTA | VP, HEAD OF EID AND EPIDEMIOLOGY | 35 | $471K |
| CHRISTOPHER PARKS | ASS. VP, VIRAL VACC. & HEAD OF DDL | 35 | $452K |
| MARIO GAGLIANO | CHIEF PEOPLE OFFICER, VP OF HR | 35 | $445K |
| DAGNA LAUFER | VP AND HEAD OF CLINICAL DEVELOPMENT | 35 | $442K |
| MIN DING | GENERAL COUNSEL/BOARD SECRETARY | 35 | $441K |
| LOUIS D SCHWARTZ | ASST. SEC., CHIEF FIN. & ADMIN OFF. | 35 | $422K |
| MARION GRUBER | VP, PUBLIC HEALTH & REG. SCIENCE | 35 | $422K |
| SANGEETHA SAGAR | VICE PRESIDENT, PDC | 35 | $420K |
| BRANDON SAFT | DEPUTY CHIEF FINANCIAL OFFICER | 35 | $278K |
board members · 13
- ALEXIS M PINTO — BOARD MEMBER
- ANNE MARTIN SIMONDS — BOARD MEMBER
- DAVID BLUMBERG — BOARD MEMBER
- ERIC PAUL GOOSBY — BOARD CHAIR
- JIM CONNOLLY — BOARD MEMBER
- JOHN W SHIVER — BOARD MEMBER
- LINDA-GAIL BECKER — BOARD MEMBER
- MARIJKE WIJNROKS — BOARD MEMBER
- MARK DYBUL — BOARD MEMBER
- RAJEEV VENKAYYA — BOARD MEMBER
- ROBERT GOLDBERG — BOARD TREASURER
- SUSAN SILBERMANN — BOARD MEMBER
- WAFAA EL-SADR — BOARD MEMBER
relationships · 95
Who they work with
- AIDS Fonds Partner — Civil society organization in the Netherlands collaborating on advocacy for global health R&D
- AIDS-Fondet Partner — Civil society organization in Denmark collaborating on advocacy for global health R&D
- Aurum Institute Partner — Collaborates with the Aurum Institute on HIV vaccine research and community engagement activities.
- Batavia Biosciences Partner — Manufacturing and development partner for rVSV-based vaccine candidates
- Battelle Partner — Preclinical research and testing partner for Sudan and Marburg virus vaccines
- BioReliance Partner — Testing and analytical services provider for rVSV-based vaccine candidates
- Biofabri Partner — Partnering with IAVI on the advanced clinical development of the MTBVAC vaccine candidate for tuberculosis.
- Biofabri S.L. Partner — Manufacturing and development partner for MTBVAC tuberculosis vaccine
- Biomedical Advanced Research and Development Authority Government — Partner in development of vaccines for Sudan, Lassa, and Marburg viruses
- Boston University’s National Emerging Infectious Diseases Laboratories Partner — Biosafety level 4 research partner for Sudan virus vaccine development
- Brigham and Women’s Hospital Partner — Clinical research partner in Lassa fever vaccine development
- CAPRISA eThekwini Partner — Clinical research partner in HIV vaccine development
- Charles River Laboratories Partner — Preclinical and clinical research support for multiple vaccine candidates
- CliniOps Partner — Clinical operations partner in Lassa fever vaccine development
- Coalition for Epidemic Preparedness Coalition — Member of coalition advancing preparedness for epidemic threats
- Coalition for Epidemic Preparedness Funder — Funder of Lassa fever vaccine development
- Collaboration for AIDS Vaccine Discovery Vaccine Immunology Statistical Center Partner — Scientific partner in HIV vaccine research
- Danida Funder — Public sector funder supporting IAVI since 2001
- Desmond Tutu HIV Foundation Partner — Partners with the Desmond Tutu HIV Foundation for HIV vaccine research and community engagement in South Africa.
- Desmond Tutu Health Foundation Partner — Clinical research partner conducting HIV vaccine trials
- Deutsche Stiftung Weltbevölkerung Partner — Civil society organization operating at EU and German levels collaborating on global health advocacy
- Duke University Partner — Research partner in HIV vaccine development
- EU PDP Coalition Coalition — Founding membership in coalition advocating for global health R&D at EU level
- East West Medical Research Institute Partner — Clinical research partner in Lassa fever vaccine development
- Emavundleni Clinical Research Site Partner — Clinical research site conducting trials for HIV vaccine candidates
- European & Developing Countries Clinical Trials Partnership Partner — Funding and research partnership supporting clinical development of Lassa vaccine
- European Commission Funder — Public sector funder supporting IAVI since 2003
- European HIV Vaccine Alliance Partner — Past EU-level research partnership on HIV vaccine development
- External Researchers Partner — Receives technical and scientific expertise from IAVI to accelerate biomedical product development.
- Facebook Partner — Social media channel for community outreach and awareness
+ 65 more
strategies · 4
How they approach the work
Named approaches extracted from this org’s sources. Where others share an approach, follow it to see the full set of orgs running it.
- Bridge Organization Model for Cross-Sector Collaborationmethodology: bridge_organization_modelBy acting as a bridge organization that connects partners across sectors, geographies, and resource levels, we accelerate biomedical innovation because synergistic collaboration leverages diverse strengths and reduces duplication in global health R&D.
- Community-Engaged Research as Scientific Disciplinemethodology: community_engaged_researchBy integrating community engagement throughout the research and product development process, we produce more acceptable, equitable, and effective public health solutions because meaningful partnerships improve scientific relevance, trial participation, and real-world adoption.
- Fair and Gender-Responsive Research Partnershipsmethodology: research_fairness_frameworkBy applying frameworks like the Research Fairness Initiative and gender mainstreaming, we strengthen the legitimacy and equity of clinical research because fair, transparent partnerships and inclusive trial design lead to more generalizable results and better health policy outcomes.
- Translational Research for Equitable Global Accessmethodology: translational_research_for_global_accessBy translating scientific discoveries into affordable, accessible vaccines and antibodies, we produce broad health and social impact because ensuring global access at the outset of development closes equity gaps in pandemic preparedness and treatment.